



Contents lists available at ScienceDirect

Journal of Diabetes and Its Complications

journal homepage: WWW.JDCJOURNAL.COM

Review article

Genetics of non-syndromic childhood obesity and the use of high-throughput DNA sequencing technologies

Ana Carolina Proença da Fonseca^a, Claudio Mastronardi^b, Angad Johar^c,
Mauricio Arcos-Burgos^b, Gilberto Paz-Filho^{c,*}^a Human Genetic Laboratory, Oswaldo Cruz Institute/FIOCRUZ, Rio de Janeiro, Brazil^b Institute of Translational Medicine, Universidad del Rosario, Bogota, Colombia^c Department of Genome Sciences, John Curtin School of Medical Research, The Australian National University, Australia

ARTICLE INFO

Article history:

Received 23 January 2017

Received in revised form 18 April 2017

Accepted 19 April 2017

Available online xxxx

Keywords:

DNA sequencing

Gene

Genetics

Leptin

Melanocortin

Obesity

ABSTRACT

Background: Childhood obesity is a serious public health problem associated with the development of several chronic diseases, such as type 2 diabetes mellitus, dyslipidemia, and hypertension. The elevated prevalence of obesity is mostly due to inadequate diet and lifestyle, but it is also influenced by genetic factors.

Objectives: To review recent advances in the field of the genetics of obesity. We summarize the list of genes associated with the rare non-syndromic forms of obesity, and explain their function. Furthermore, we discuss the technologies that are available for the genetic diagnosis of obesity.

Results: Several studies reported that single gene variants cause Mendelian forms of obesity, determined by mutations of major effect in single genes. Rare, non-syndromic forms of obesity are a result of loss-of-function mutations in genes that act on the development and function of the hypothalamus or the leptin-melanocortin pathway. These variants disrupt enzymes and receptors that play a role in energy homeostasis, resulting in severe early-onset obesity and endocrine dysfunctions. Different approaches and technologies have been used to understand the genetic background of obesity. Currently, whole genome and whole exome sequencing are important diagnostic tools to identify new genes and variants associated with severe obesity, but other approaches are also useful at individual or population levels, such as linkage analysis, candidate gene sequencing, chromosomal microarray analysis, and genome-wide association studies.

Conclusions: The understanding of the genetic causes of obesity and the usefulness and limitations of the genetic diagnostic approaches can contribute to the development of new personalized therapeutic targets against obesity.

© 2017 The Authors. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Childhood obesity has been recognized as one of the most serious public health problems of the 21st century,¹ and is defined by the World Health Organization as an abnormal or excessive accumulation of body fat, sufficient to cause adverse health effects. The body mass index (BMI, calculated by dividing weight [kilograms] by the height squared [meters]) is a clinical standard measure of overweight and obesity and provides an estimate of adiposity in children and adults. In the measurement of children and adolescents, BMI requires to be adjusted for both age and gender.^{1,2}

The prevalence of childhood obesity has increased at alarming rates, affecting populations from developed and developing countries.^{3–5} The problem is global and tends to increase with the income level of these countries.⁶ In 2013, the prevalence of overweight and obesity in developed countries was 23.8% for boys and 22.6% for girls; in developing countries, it was 12.9% for boys and 13.4% for girls.⁷ The prevalence of childhood obesity in some European countries and the United States (US) has apparently reached a plateau; nevertheless, the prevalence continues to increase in developing countries.⁸ Recent data estimate that there are more than 41 million children worldwide under 5 years of age who are overweight or obese. Among those overweight children, almost half of them live in Asia and one quarter in Africa.^{1,5}

Unfortunately, obese children have more than a 50% probability of carrying their adiposity into adulthood, while nonobese children have 10%.⁹ Furthermore, childhood obesity is a risk factor for the development of different comorbidities at a younger age which used to be considered as diseases seen only in the adult, including type 2 diabetes mellitus, dyslipidemia, hypertension, obstructive sleep apnea

Financial Conflict: None.

This article did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

* Corresponding author at: 131 Garran Rd, Acton, ACT 2601, Australia.

E-mail addresses: u4842377@anu.edu.au (A. Johar), gilberto.pazfilho@anu.edu.au (G. Paz-Filho).

<http://dx.doi.org/10.1016/j.jdiacomp.2017.04.026>

1056-8727/© 2017 The Authors. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: da Fonseca ACP, et al. Genetics of non-syndromic childhood obesity and the use of high-throughput DNA sequencing technologies. *Journal of Diabetes and Its Complications* (2017), <http://dx.doi.org/10.1016/j.jdiacomp.2017.04.026>

Table 1
Rare non-syndromic forms of early-onset obesity.

Gene ID	Gene name	Chromosome location	Inheritance	Protein function	Additional features	Reference
<i>LEP</i>	Leptin	7q32.1	Autosomal recessive	Stimulates anorexigenic pathway and inhibits the orexigenic pathway	Low levels of leptin, insulin resistance, dyslipidemia, susceptibility to infection diseases and hypogonadotropic hypogonadism	Paz-Filho et al., 2010 ²⁴ ; Montague et al., 1997 ²⁵
<i>LEPR</i>	Leptin receptor	1p31.3	Autosomal recessive	Leptin receptor	Immune dysfunctions, hypogonadotropic hypogonadism, growth hormone deficiency and hypothyroidism	Clement et al., 1998 ²⁶ ; Saeed et al., 2014 ²⁷ ; Farooqi et al., 2007a ²⁸ ; Farooqi et al., 2007b ²⁹
<i>PCSK1</i>	Proprotein convertase subtilisin/kexin type 1	5q15	Autosomal recessive/dominant	Proteolytic processing of prohormones and proneuropeptides	Diabetes insipidus, growth hormone deficiency, malabsorptive diarrhea, hypogonadism, adrenal insufficiency and hypothyroidism	Farooqi et al., 2007b ²⁹
<i>POMC</i>	Pro-opiomelanocortin	2p23.3	Autosomal recessive	Protein precursor of melanocortin family that transmits leptin effects to MC4R and regulates the adrenal growth	Adrenal insufficiency and pigmentation abnormalities	Kühnen et al., 2016 ³⁰
<i>TUB</i>	Tubby bipartite transcription factor	11p15.4	Autosomal recessive	Modulates anorexigenic neuropeptides*	Retinal dystrophy	Borman et al., 2014 ³¹
<i>SH2B1</i>	Src homology 2 B adapter protein 1	16p11.2	*	Modulates cell signaling in response to leptin and other hormones	Insulin resistance, maladaptive behavior, delayed speech and language development	Doche et al., 2012 ³² ; Rui, 2014 ³³
<i>MC4R</i>	Melanocortin-4 receptor	18q21.3	Autosomal co-/dominant	Transmits the anorexigenic and orexigenic effects, controlling satiety and energy expenditure	Hyperinsulinemia, increased linear growth or isolated obesity phenotype	Doulla et al., 2014 ³⁴ ; Farooqi, 2003 ³⁵ ; Melchior et al., 2012 ³⁶ ; Farooqi, 2015 ³⁷
<i>MRAP2</i>	Melanocortin 2 receptor accessory proteins 2	6q14.3	Autosomal dominant	Regulates melanocortin receptors	*	Asai et al., 2013 ³⁸ ; Schonnop et al., 2016 ³⁹
<i>KSR2</i>	Kinase suppressor of ras 2	12q24	*	Involved in cellular fuel oxidation	Low heart rate, reduced basal metabolic rate and insulin resistance	Pearce et al., 2013 ⁴⁰ ; Costanzo-Garvey et al., 2009 ⁴¹
<i>SIM1</i>	Single-minded homolog 1	6q16.3	Autosomal dominant	Regulates the development and function of the paraventricular nucleus	Accelerated linear growth, impaired concentration, memory deficit, emotional lability and autistic spectrum behavior	Ramachandrapa, 2013a ⁴² ; Holder et al., 2000 ⁴³
<i>BDNF</i>	Brain-derived neurotrophic factor	11p13	Autosomal dominant	Regulates the development, survival and differentiation of neurons	Hyperactivity, impaired memory, reduced nociception, delayed speech and language development	Gray et al., 2006 ⁴⁴
<i>NTRK2</i>	Neurotrophic tyrosine kinase receptor type 2	9q22.1	Autosomal dominant	BDNF receptor	Development delay as well as short-term memory and nociception impaired	Yeo et al., 2004 ⁴⁵
<i>LRP2</i>	Low-density lipoprotein receptor 2	2q31.1	Autosomal dominant	Binds to the long-form of LEPR and activates STAT3 signaling	Puberty delay, decelerated linear growth, hypothyroidism, insulin resistance and elevated levels of prolactin	Paz-Filho et al., 2014 ⁴⁶

Notes: *Not yet elucidated.

and steatohepatitis.¹⁰ They also have psychosocial and emotional well-being consequences, since those children are more likely to have anxiety, depression, poor self-esteem and become victims of bullying.^{11–13} The increased risk for developing obesity-related disease is associated with premature death and leads to increased healthcare utilization and expenditures.^{14,15} Children with higher BMI utilize emergency department and outpatient clinic visits more frequently when compared to underweight/normal weight children.¹⁶ In the US, elevated BMI among children and adolescents costs 14.1 billion dollars in additional prescription drugs, emergency department and outpatients clinics visits per year.¹⁷ Since obese children and adolescents have an increased risk of remaining obese as adults, the Brookings Institution has estimated that obese people have lifetime societal costs nearly 92,000 dollars greater than normal weight subjects.^{18,19}

The etiology of childhood obesity is extremely complex, being clearly influenced by environmental, behavioral, genetic and ecological factors.^{10,20} Common forms of obesity, which are present in most cases, are caused by a combination of environmental factors with many gene variants of minor effect. However, at least ~7% of non-syndromic early-onset severe obesity (defined by onset before age 5 and body mass index over three standard deviations above normal) are monogenic, thereby caused by gene variants of major effect^{21–23} (Table 1). In the large universe of obesity, that small percentage accounts for a substantial number of cases: considering

that between 1.8% to 5.6% of Australian children are severely obese,^{47,48} there are between 5000 and 18,000 cases of monogenic forms of NEOSO (non-syndromic early-onset severe obesity), which remain largely undiagnosed.

Population-based approaches such as genome-wide association studies (GWAS), and other approaches that can be employed at the individual level, such as sequencing of candidate genes and of the whole genome or exome, have led to the identification of at least 146 genetic variants associated with body mass index (BMI) or waist-to-hip ratio phenotypes.⁴⁹ Furthermore, at least twelve gene variants directly involved in monogenic forms of non-syndromic human obesity have been identified,⁵⁰ including a novel variant in the low-density lipoprotein receptor 2 (*LRP2*) gene, identified by our group.⁴⁶

The identification of obesity-associated genes has already contributed to the clarification of unsuspected biological pathways involved in the control of energy balance,⁵¹ such as the leptin-melanocortin pathway, and in the neuronal differentiation of the paraventricular nucleus.⁵² While there is robust evidence that the heritability of body weight is prominent, currently only a small fraction of the BMI variance can be explained by genetic factors.⁵³ Therefore, either most of the obesity genes remain to be discovered, or their interaction is unknown.

To broaden our understanding of the importance of gene variants on non-syndromic excess body weight, several genomic- and

genetic-based strategies have become available, such as GWAS and, more recently, whole genome sequencing (WGS), whole exome capture (WEC) and tagged next generation sequencing. This review is intended to provide comprehensive knowledge to clinicians and clinical researchers on the genetics of obesity. It will initially present what is currently known about the genetics of obesity, and will subsequently discuss the currently available technologies for the investigation of the genetic causes of excessive adiposity.

2. Genetic basis of obesity

Many different hypotheses have been proposed to explain the origin of the obesity epidemic. It is broadly accepted that the two major putative contributors are specific food marketing and consumption habits, and decrease in physical activity. However, there are others contributors, such as infections, maternal age, sleep debt, endocrine disruptors (such as industrial chemicals), reduction in ambient temperature variations, intrauterine and intergenerational effects, and drug-induced weight gain.⁵⁴ Despite the importance of all these contributors, it is known that genetic factors have a key role in the risk of one becoming obese.

The percentage of obesity that can be attributed to genetics varies from 6 to 85%.⁵⁵ Despite high estimates of heritability and decades of molecular genetic investigation, a very small fraction of genes associated with obesity have been identified. Twin studies have been used to understand the genetic component of obesity.⁵⁶ Bouchard et al.⁵⁷ through experiments of overfeeding and regular exercises, reported that monozygotic twins had more similar changes of body weight, body composition and energy expenditure when compared to dizygotic twins. Additionally, adoption studies showed a strong relationship between the BMI of biological parents and their adopted children; however no similarity was found with adoptive parents. These studies suggest that obesity and adiposity are inheritable factors.⁵⁸

2.1. Polygenic obesity

It is well-characterized that the obesity epidemic is not caused by single gene disorders, but actually has a complex genetic background. The patient with common obesity has many genetic susceptibility variants, which have a minor effect on body weight.⁵⁹ The effect of genes on the pathogenesis of obesity is more frequently stronger when combined with other genes and the environment. The association of these genes with obesity has been evaluated through several approaches, such as linkage analysis, candidate gene sequencing and GWAS.

Over the past years, genetic epidemiological studies have identified several genes which play important biological roles in human obesity. Recently, Locke et al.²² carried out GWAS and Metachip meta-analysis for BMI. Data was analyzed from 339,224 individuals of 125 different studies. A total of 97 BMI-associated loci were identified, of which 56 were novel. Many of these loci were in/near genes which play a role in different biological processes, for example, the neuronal development (*FAIM2*, *PTBP2* and *ST5*), hypothalamic expression and regulatory function (*TMEM18*, *SCG3* and *GRP*); limb development (*RARB*, *TFAP2B* and *LMX1B*), lipid biosynthesis and metabolism (*CYP27A1*, *CYP17A1* and *NR1H3*), cell proliferation and survival (*PARK2* and *OLFM4*), and immune system (*IL22RA2*, *MAN1A1*, *IFNGR1*). Furthermore, some genes have previously been associated with severe early onset obesity (*BDNF*, *MC4R*, *SH2B1*, *TUB* and *POMC*). These 97 loci account for 2.7% of BMI variation and it was suggested that their common variants influence nearly 21% cases of obesity. Despite this robust study, most of the genetic variability in human obesity remains unknown.

2.2. Mendelian or monogenic forms of non-syndromic obesity

Over the last 15–20 years, it has been characterized that single gene mutations can cause severe early-onset obesity in humans.^{60,61} Assessment of such cases has already provided seminal information on genes involved in critical pathophysiological pathways that can lead to obesity. These genes encode enzymes and receptors that have a physiologic role in the development of the hypothalamus and the leptin-melanocortin system.

2.2.1. The hypothalamic development and the appetite control

The hypothalamus is the region of the brain involved in the regulation of the body's temperature, fertility, thirst and appetite.⁶² The role of the hypothalamus in severe obesity has been postulated since the early twentieth century. Initially, chemical and electrical experiments that damaged the hypothalamus of cats and mice were correlated with an increase or loss of weight, depending on the size and location of the lesion. These experiments suggested the existence of a specific circuit in the hypothalamus that promoted or suppressed food intake.^{63,64} In humans, patients with tumors in the hypothalamic region are obese, suggesting an involvement of the hypothalamus in the regulation of body weight.⁶⁵ Nowadays, it is known that the hypothalamus acts to maintain energy homeostasis, by receiving information about the body's nutritional status and energy stores, through neural and hormonal signals.^{61,66}

The neuronal differentiation of the hypothalamus is controlled by several proteins, including brain-derived neurotrophic factor (BDNF), transcription factor single-minded 1 (SIM1) and the tyrosine kinase receptor (TRKB).^{62,67} Interestingly, pathogenic mutations which disrupt these protein functions can lead to severe onset-obesity in humans.^{42,44,45}

The development of obesity results from imbalance between energy intake and expenditure over a prolonged period.⁶⁸ One of the most important pathways responsible for controlling food intake and body weight is the leptin-melanocortin system, located in the hypothalamus. This system is an important pathway to energy balance that integrates information from energy stores and nutritional status in peripheral organs with a neural circuit.⁶⁶

This pathway is activated when leptin, produced by adipocytes, crosses the blood-brain barrier and binds to its receptors, localized in two different groups of neurons in the arcuate nucleus of the hypothalamus. Both groups of neurons act on the regulation of food ingestion and energy expenditure, which are important for energy homeostasis. One of these groups expresses neuropeptide Y (NPY) and agouti-related protein (AgRP) that stimulates food intake (orexigenic pathway), while the other expresses proopiomelanocortin (POMC) and cocaine and amphetamine-regulated transcript (CART) which inhibits food consumption (anorexigenic pathway).^{69,70}

The brain can control energy homeostasis since it receives information about the body's nutritional status and energy stores by peripheral hormones. When the body has food restrictions, is fasting and/or has a decreased energy stock, the stomach secretes ghrelin that binds to the ghrelin receptor, localized in the orexigenic neurons, increasing the production of NPY and AgRP. The orexigenic neurons project to the paraventricular nucleus (PVN) of the hypothalamus and their neuropeptides act as antagonists of melanocortin receptors, which stimulate food intake and decrease the basal energy expenditure. However, when the body has adiposity and/or energy replacement, the white adipose tissue secretes leptin that binds to leptin receptor (LEPR), localized in the orexigenic neurons, suppressing this pathway. Furthermore, leptin binds to its receptor on anorexigenic neurons, increasing the production of POMC and CART. The POMC hormone is a protein precursor which is processed and cleaved into α melanocyte stimulating hormone (α -MSH) by proprotein convertase 1/3 (PC1/3) and binds to the melanocortin-4




Fig. 1. Hypothalamic mechanisms of appetite control. Hypothalamic leptin-melanocortin pathway regulated by leptin and ghrelin. Leptin activates anorexigenic neurons proopiomelanocortin (POMC) and cocaine and amphetamine-regulated transcript (CART) which inhibit food consumption, and inhibits neuropeptide Y (NPY) and agouti-related protein (AgRP), stimulating food intake (orexigenic pathway). Ghrelin is the only orexigenic peptide, secreted by the stomach.

receptor (MC4R), located in the paraventricular nucleus (PVN). Activation of MC4R by α -MSH and CART increases a satiety signal, suppressing appetite and increasing basal energy expenditure.^{71–73} Interestingly, mutations in genes involved the leptin-melanocortin pathway demonstrate the critical role of energy balance and have been associated with development of severe early-onset obesity.^{50,74,75} Fig. 1 summarizes the hypothalamic mechanisms involved in appetite control.

2.2.2. Recessive forms of non-syndromic monogenic obesity

The first evidence of monogenic obesity was found in rodents in the early 1950s. It was reported that *ob/ob* mutant mice have four times higher weight than normal animals.⁷⁶ Through further studies, Coleman⁷⁷ discovered that *ob/ob* mice have a deficiency of the signaling pathway from adipose tissue, which regulates food intake and metabolism. After positional cloning and sequencing, the leptin gene (*lep*) was identified and characterized.⁷⁸ In humans, pathogenic mutations in the *LEP* gene are associated with low levels of leptin, hyperphagia and severe early-onset obesity.^{25,79,80}

For over 15 years, researchers have been evaluating phenotypic findings and the effects of leptin replacement in less than a dozen of the ≤ 40 leptin-deficient individuals identified in the world. Our group has been following one child and three adults from a consanguineous extended Turkish family (summarized in^{24,81,82}). These individuals have a Mendelian recessive mutation in the *LEP* gene, consisting of a C \rightarrow T substitution in codon 105 of this gene, resulting in an Arg \rightarrow Trp replacement in the mature protein. Three of them are the only leptin-deficient patients identified during adulthood in the world to date. Physiological doses of recombinant methionyl human leptin (r-metHuLeptin, metreleptin, Aegerion Pharmaceuticals, Inc., USA, 0.02–0.04 mg/kg/day) were started at ages 5 (boy), 27 (man), 30 and 40 (women), leading to significant improvements in body weight, endocrine function and behavior.⁸³ Leptin replacement was lifesaving, as eight members of this family with NEOSO, whom we presume to have been leptin-deficient, died of immune deficits in childhood.

The study of recessive forms of monogenic extreme obesity has been useful in delineating the role of genes from the leptin-

melanocortin pathway. However, these recessive forms of obesity due to functional mutations in the *LEP* are very rare, and mostly identified in families with high levels of consanguinity. To date, ≤ 40 individuals have been found to be homozygous for each of these mutations. However, a systematic effort to sequence *LEP* in 73 individuals with NEOSO revealed that 22% were homozygous for *LEP* mutations, resulting in impaired leptin signaling.⁸⁰ This study showed that a systematic genetic examination of early-onset severe obesity, even by focusing on a few genes, could reveal a meaningful percentage of monogenic cases of obesity. It is important to note that, although most patients with the leptin-deficient phenotype have low or undetectable serum leptin levels, one patient had detectable, but biologically inactive serum leptin.⁸⁴

Besides *LEP*, homozygous loss of function mutation of its receptor *LEPR* is associated with severe hyperphagia and early-onset extreme obesity in humans. Initially, homozygous mutations in *LEPR* were identified in patients characterized by hyperphagia, early-onset morbid obesity, failure of pubertal development and impairment in secretion of growth hormone and thyrotropin. These patients had a base substitution in the splice donor site of exon 16, which results from skipping this exon and generates a truncated receptor that lacks both the transmembrane and intracellular domains.²⁶ Afterwards, Farooqi et al.²⁸ reported eight severely obese subjects that had nonsense or missense *LEPR* mutations. The nonsense mutations were predicted to result in a lack of all receptor isoforms, and the missense variants impaired receptor signaling. Recently, two novel frameshift mutations were identified in severely obese children by whole-exome sequencing. Both mutations generate an abnormal protein that lacks the leptin binding receptor domain (CRH2), affecting all isoforms.⁸⁵ On the whole, congenital deficiency of *LEP* or *LEPR* disrupts leptin signaling and is characterized by similar clinical data.²⁸

POMC is a complex propeptide expressed in the hypothalamus, pituitary gland and brainstem that is activated by tissue-specific post-translational processing.⁶² POMC generates a family of melanocortin peptides, for example the adrenocorticotrophic hormone (ACTH) and α -, β -, and γ -melanocyte-stimulating hormones (MSH). These peptides have an important role on skin pigmentation, the control of

adrenal growth and energy balance.⁸⁶ Different mutations that inactivate the *POMC* gene have been reported in children, leading to severe early-onset obesity, adrenal insufficiency and pigmentation abnormalities.^{87,88} Krude et al.⁸⁸ reported the first human description of congenital deficiency of POMC. They identified two unrelated children who had severe childhood obesity, adrenal hypoplasia, red hair and pale skin. One patient had a compound heterozygous variant for two nonsense mutations and the second had a homozygous variant for the new initiation site of translation, localized in the 5-untranslated region. Although *POMC* mutations could result in a pigmentation abnormality, this characteristic was absent in different case reports.^{24,46,82,89} For example, Mendiratta et al.⁹⁰ identified an 18-month-old female with congenital adrenal insufficiency caused by a homozygous C → A substitution in codon 231 of *POMC* gene, which was predicted to result in a premature stop codon. The clinical phenotype of the patient was similar to previous reports, however the child had dark colored hair and dark roots. More recently, another interesting variation in the classical phenotype of POMC deficiency was described by Samuels et al.⁹¹ They reported a 4-year-old girl and a 4-month-old boy who had high circulation levels of ACTH caused by variants that generate non-functional peptides, but immunologically detectable.

In the last 20 years, researchers have identified variants in *POMC* that cause congenital deficiency; however, only the adrenal insufficiency phenotype is treatable, by using hydrocortisone.⁹² This year, Kühnen et al.³⁰ reported two obese *POMC*-deficient patients that were treated with daily subcutaneous synthetic melanocortin (setmelanotide), resulting in body fat loss, decreased appetite and darkening of the skin and hair. Setmelanotide, also known as RM-493, binds to the MC4R and activates the anorexigenic pathway, substituting the lack of MSH in those patients. Although this study shows a limitation in the number of patients, setmelanotide may offer a potential treatment for *POMC* deficiency in the future. Furthermore, they speculated that synthetic melanocortin might be useful for treating *LEPR* and *PCSK1* deficiency patients.

In addition, null mutations in proprotein convertase subtilisin/kexin type 1 gene (*PCSK1*) cause a rare non-syndromic form of obesity.⁹³ *PCSK1* encodes the PC1/3 that is expressed in neural and endocrine tissues.⁹⁴ In the brain, PC1/3 is highly expressed in the hypothalamus where it acts on cleavage processing of POMC to α -MSH.^{66,95} Several cases of PC1/3 deficiency were reported with hyperphagia, central diabetes insipidus, severe malabsorptive diarrhea and other endocrines dysfunctions. This deficiency could be explained by mutations that affect protein maturation and generate impairment in the catalytic activity, resulting in a truncated protein or lack of protein.^{29,93,96–98} Although PC1/3 deficiency is described as an autosomal recessive disorder, the severe obesity phenotype has been associated with loss of one wild-allele. Philippe et al.⁹⁹ identified a heterozygous non-synonymous mutation that is co-segregated with obesity in three generations of a French family. This variant, located in the second exon of *PCSK1*, affects both mutant and wild-type proteins activity in vitro. This autosomal dominant inheritance of obesity may be explained by the truncated propeptide which also interferes with the function of the wild-type protein.

Recently, Borman et al.³¹ identified a homozygous frameshift mutation in tubby bipartite transcription factor gene (*TUB*) which was associated with early-onset obesity as well as retinal dystrophy in humans. This variant is found in a conserved region of *TUB* family resulting in a truncated protein, which has an incorrect localization in the cell. Moreover, loss of function mutation in the *Tub* gene also induces obesity in mice.¹⁰⁰ The role of *TUB* in energy balance has not been totally elucidated; however it is expressed in different regions of the hypothalamus, including the arcuate nuclei and paraventricular nuclei. Additionally, experimental data suggests that the *TUB* protein acts on modulating anorexigenic neuropeptides, and low levels of *TUB* expression result in increased food intake and adiposity.¹⁰¹

2.2.3. Dominant forms of non-syndromic monogenic obesity

The progress in understanding the obesity background is mostly due to the identification of rare genetic forms. Although several gene variants have been identified to cause recessive forms of obesity, heterozygosity for deleterious mutations in *BDNF*, *NTRK2*, *SIM1*, *MC4R*, *SH2B1*, *MRAP2* and *LRP2* have also been associated with severe early-onset obesity.

BDNF, *NTRK2* and *SIM1* are responsible for coding important proteins to the development of the hypothalamus.⁶² *BDNF* and its receptor TrkB (encoded by *NTRK2*) are involved in the proliferation, survival, and differentiation of neurons in the central nervous system, especially the hypothalamic neurons.¹⁰² *SIM1* is a transcription factor that plays a major role in the development and function of the paraventricular nucleus, a critical region for food intake regulation.⁴³ In humans, pathogenic mutations in those genes are associated with hyperphagia and severe obesity phenotype. A de novo heterozygous missense mutation (Y722C) in *NTRK2* was found in an eight-year-old male patient with severe obesity, nociception, impaired short-term memory and learning.⁴⁵ Functional analysis demonstrated that Y722C leads to TrkB dysfunction.¹⁰³ Furthermore, a de novo paracentric inversion in chromosome 11 (46, XX, inv (11)(p13p15.3)), which disrupts one copy of the *BDNF* gene, was identified in a child with severe obesity, impaired cognitive function and hyperactivity.⁴⁴

Obesity also has been associated with *SIM1* haploinsufficiency in humans. Initially, a female patient was identified with severe early-onset obesity that had a balanced translocation (46, XX, t(1;6)(p22.1;q16.2)), leading a disruption of *SIM1* in one allele.¹⁰⁴ In addition, rare missense mutations in *SIM1* have been associated with obesity.^{105,106} Recently, the coding region of *SIM1* was sequenced in 2100 severe early-onset obesity probands and in 1680 controls, identifying 13 heterozygous variants in 28 patients, in which nine of these mutations would reduce the activity of *SIM1* in vitro. Among these patients with pathogenic variants, 11 individuals had evidence of cognitive deficit including impaired concentration, emotional lability and memory deficit, in addition to severe early-onset obesity.¹⁰⁵ A similar analysis was performed in 561 overweight/obese subjects, and identified four heterozygous rare nonsynonymous variants in *SIM1* gene, in which two of these mutations caused impairment in the *SIM1* function.¹⁰⁶ Therefore, *BDNF*, *NTRK2* and *SIM1* haploinsufficiency are associated with severe early-onset obesity as well as cognitive impairment in humans.

MC4R is the receptor for α -MSH and, as such, plays a key role in energy homeostasis, food intake and body weight, since it regulates satiety.¹⁰⁷ Consistent with this role, loss of function *MC4R* mutations are associated with increased appetite that leads to severe early-onset obesity in humans.^{35,108} Nowadays, more than 150 variants are known, and the prevalence of deleterious *MC4R* variants ranges from 0.5% up to 5% in obese children.^{60,109,110} *MC4R* mutations are the most common genetic cause of monogenic obesity and also contribute to polygenic forms.^{111,112} The rare cases of *MC4R* deficiency are inherited in a co-dominant form.^{37,113} Several cases of *MC4R* deficiency described patients with early-onset obesity, hyperphagia, severe hyperinsulinemia and increased linear growth, although the endocrine and anthropometric phenotypes were not confirmed in other reports.^{34–36} Recently, the *MC4R* gene was sequenced in a large cohort of obese children and adolescents from Germany. *MC4R* mutations were detected in 22 probands, in which fourteen patients had variants causing loss of function or impaired the receptor signaling.¹¹⁴ Since pharmacological drugs are being developed to treat *MC4R*-deficient patients, it is extremely important to identify pathogenic mutations.^{115,116}

It has been recognized that accessory proteins can regulate melanocortin receptors such as MC4R.^{38,42} Melanocortin 2 receptor accessory protein 2 (*MRAP2*) is expressed in regions involved in energy balance, such as the hypothalamus and brainstem.

Furthermore, MRAP2 has been shown to interact with MC4R; its mRNAs is coexpressed in the brain, suggesting an involvement of MRAP2 in the energy homeostasis.^{38,117} To explore if MRAP2 mutations have an important role in human obesity, the coding region of this gene was screened in 483 children and adolescents with extreme obesity and 630 individuals with normal weight. Three missense mutations were detected among obese subjects, all in heterozygosis. In vitro functional analyses revealed that one of nonsynonymous variant (p.Gln174Arg) causes a partial MC4R loss of function.³⁹ Additionally, four heterozygous mutations were identified in patients with severe early-onset obesity, suggesting that MRAP2 variants may contribute to rare cases of monogenic obesity.³⁸

Src homology 2 B adaptor protein 1 (*SH2B1*) encodes a cytoplasmic adaptor protein, which modulates leptin-melanocortin signaling.³³ Heterozygous frameshift and missense variants in *SH2B1* were associated with obesity, insulin resistance and behavioral abnormalities, including a tendency for social isolation and aggressive behavior.^{32,118} Furthermore, severe early-onset obesity and severe insulin resistance phenotypes were reported in a patient with a 220-kb segment deletion of chromosome 16p11.2, where several genes are located, including *SH2B1*.¹¹⁹ Several SH2B1 variants in heterozygosis have been reported and one in homozygosis. All variants except one co-segregated with obesity in families in a classical Mendelian manner.¹¹⁸

Additionally, kinase suppressor of ras 2 (*KSR2*), which acts as a scaffolding protein, was previously associated with obesity.⁴⁰ KSR2 plays a role in energy homeostasis, insulin sensitivity and cellular fuel oxidation. Early studies demonstrated that deletion of *Ksr2* in mice is associated with obesity and insulin resistance.^{41,120} Furthermore, *KSR2* is located in a chromosome region linked to obesity and type 2 diabetes.^{121,122} To examine whether KSR2 is involved in human obesity, the coding region and intron/exon junctions of *KSR2* were screened in 2101 patients with severe early-onset obesity and 1536 normal weight controls. A total of 31 different rare frameshift, nonsense or missense mutations were identified, 27 in severely obese subjects and 7 in controls. Most of the variants impaired the KSR2 function and were found in a heterozygous manner. Curiously, some loss of function mutations in *KSR2* were not co-segregated with severe obesity, suggesting that other factors may modulate the phenotype caused by some variants.⁴⁰

More recently, we added *LRP2* to the list of genes associated with dominant monogenic obesity.⁴⁶ By submitting three Brazilian patient-family trios to WEC and parallel sequencing studies, we identified one male teenager with compound heterozygous mutations in the *LRP2* gene (confirmed by Sanger sequencing). LRP2 binds to the long-form leptin receptor (LepRb), forming a complex that is co-localized and subjected to endocytosis in the hypothalamic neurons. Subsequently, the endocytosis of this co-localized complex leads to the activation of signal transducer and activator of transcription 3 (STAT3) signaling in hypothalamic neurons. As a consequence, food intake and body weight are decreased. In the absence of functional LRP2, STAT3 signaling is decreased. Therefore, hunger is stimulated and satiety decreased,¹²³ leading to obesity.

3. Approaches for the genetic diagnosis of obesity

3.1. Linkage analysis

Linkage analysis is the most used method for the genetic mapping of Mendelian traits with familial aggregation. This genetic approach accounts for the transmission pattern from parents to offsprings, as well as the respective affection status of the family members, along with their allele frequencies for variants/loci under investigation. This quantification process also considers instances of recombination

among loci being tested. All of this information is used to generate a likelihood ratio under the alternate hypothesis (i.e. evidence of linkage or co-segregation between variants and the disease). This is conditional on the premise that the recombination fraction is <0.5 , and rejection of the null hypothesis (no linkage/co-segregation). Therefore, two linked loci yield a recombination frequency that is less than 0.5 according to the laws of segregation and independent assortment hypotheses, represented by a logarithm of the odds (LOD) score. It is used to identify loci which co-segregate with a disease or specific phenotype within related individuals. It is noteworthy that the discovery of the leptin gene by positional cloning used the concept of linkage in its methodological approach.⁷⁸

The availability of nuclear families (including parents and offspring) or extended families displaying the obesity phenotype would constitute a suitable paradigm to perform linkage analyses. It is also noteworthy to remark, that in this type of approach, genetic homogeneity is maximised, which also renders these analyses very powerful. This is the case even for small numbers of families, provided that cohorts are selected from genetically homogeneous populations. On the other hand, association studies are only able to detect allele-frequency differences between cases and controls of lower phenotypic effect and that requires extremely large sample sizes. Thus, the fact that the LOD score calculation accounts for many of these factors, and not just allele frequency differences between cases and controls, it renders a much more powerful outcome than GWAS and/or other association analyses. This would be especially the case if patients are carrying extreme phenotypic forms of the disease, when trying to identify rare variants of major effect. GWAS, on the other hand often relies on common-disease common-variant hypothesis, so at best they can only detect variants of small effect. In order to detect rare-variants of major effect in association studies, very large sample sizes are needed. The latter can be addressed with algorithms that use rare-variant collapsing/grouping strategies at the gene level (see below), but they do not have the advantages of mathematically incorporating information of familial segregation patterns, as mentioned earlier for linkage analyses.

Finally, new linkage algorithms have emerged that are capable of identifying de novo mutations as candidate disease variants. Thus, with all of these advantages, there have been new strategies developed to combine the strengths of linkage and association analyses.¹²⁴ While this has the advantages of evaluating familial co-segregation, it will also ensure that the variants under investigation are not overrepresented in sets of unaffected controls, which may be unrelated to the families tested for linkage. In consideration of all of this, one has to state then, that linkage analyses are at least as powerful as association studies.

3.2. Candidate gene sequencing

This approach aims to study genetic markers in candidate genes for a specific characteristic. These genes are previously selected by evidence of involvement in relevant pathways to the phenotype studied as well as earlier results that showed a possible association of the gene and the disease.¹²⁵ The candidate variants of this gene are then submitted to Sanger sequencing for validation, and their sequences are compared against the reference human genome. Sanger sequencing has been the gold-standard for validating genomic findings for over 2 decades. In well-selected cases, sequencing can lead to a genetic diagnosis in up to 46% of patients.¹²⁶ Currently, next generation sequencing is a very cost-effective first line approach, even when there is high suspicion for a specific gene. Sanger sequencing is then employed to validate the next generation sequencing findings.

3.3. Chromosomal microarray analysis

Different studies are focused on identifying copy number variations (duplications or deletions or chromosomal segments; CNV) to increase the knowledge on obesity susceptibility. Previous studies reported that individuals with severe early-onset obesity have an enrichment of CNVs, suggesting that variation may represent a risk for this disease.¹²⁷ Considering that fact, the chromosomal microarray analysis has been a useful tool to search for CNVs in the genome.¹²⁸

Chromosomal microarray is particularly useful for identifying microdeletions, microduplications, and most of abnormalities regarding chromosomal number. It can also, although with less power, identify most of the non-balanced rearrangements, imprinting, triploidy, and punctual mutations. However, it cannot identify larger deletions and mutations, such as fragile X syndrome, and balanced rearrangements, such as inversions and balanced translocations.

3.4. GWAS

The new age of technology has been allowing the identification of common variants associated with complex multigenic disorders. In GWAS, a huge number of DNA markers across the genome is scanned, and through statistical analysis, it is possible to identify the loci associated with disease or specific phenotype.⁶⁰ Until now, GWA methodologies have been found in 119 common gene variants as being linked to obesity susceptibility or related traits.⁵⁰ The fat mass and obesity-associated gene (*FTO*) was considered the first locus found in GWAS of obesity. Furthermore, this result was replicated in different studies including cohorts of European and African descent. These researchers identified a cluster of common variants in the first intron of *FTO* that is associated with increased BMI. Moreover, these common polymorphisms were associated with body weight and body fat distribution.^{129–131}

More recently, a GWAS meta-analysis study identified 97 loci linked to obesity explaining 2.7% of BMI variation. Although GWAS have been an efficient and robust method to identify regions that are predisposed to obesity, the results are not strong enough to explain the estimated heritability of this disease.²² Furthermore, GWAS are a useful approach for identifying common variants and loci associated with polygenic obesity at a population level, but not applicable in the diagnosis of Mendelian form at the individual level. Thus, more molecular studies and new methodologies are required to understand the genetics of obesity.

3.5. Next generation sequencing

The comprehension of the genetic background of obesity has required different molecular strategies, since it is not completely elucidated yet. Recently, a more precise and fast screening approach has been developed and applied successfully in the diagnosis of monogenic forms of obesity.^{59,132} Next generation sequencing (whole-genome and whole-exome) allows the identification of mutations that might lead to personalized medicine resulting in a better life for the patient.⁹⁹ One of the most common examples is the severely obese patients carrying loss of function mutations in the *LEP* gene, who can be treated with recombinant leptin.^{81,133}

Next generation sequencing (NGS), particularly WEC, has been used in the clinics for the diagnosis of diseases such as neurodevelopmental and autoimmune disorders.^{134,135} It can provide a diagnosis in 22%–46% of cases, and is indicated by the American College of Medical Genetics and Genomics (ACMG) in case the phenotype and family history strongly suggest an unspecific genetic disease, when there is significant genetic heterogeneity, and when other specific tests are negative.¹³⁶ Sequencing of trios (both biological parents, besides the proband) leads to higher chance of discovery of significant mutations (30%, vs 23% when just the proband is sequenced). Besides, it

improves the detection of de novo mutations and of compound heterozygotes.¹³⁷ When siblings are sequenced, the chance of discovery of recessive mutations is increased; singleton sequencing leads to higher diagnostic rates in children (23%, vs. 18% in adults).¹³⁸

Currently, whole-exome sequencing has become more commonly used to identify variants, since it is more affordable than the whole-genome sequencing, and it covers 95% of the protein-coding genome, comprised by ~20,000 genes. The application of whole-exome sequencing in the obesity field has recently begun, but it already helped to identify novel genes associated with severe early-onset obesity not detected from previous approaches (*KSR2*, *SH2B1* and *LRP2*).^{32,40,46,118} Additionally, Saeed et al.⁸⁰ analyzed 73 children with severe obesity from Pakistan and identified loss of function homozygous variants in *LEP*, *LEPR* and *MC4R* genes, explaining 30% of cases. The same group sequenced the coding region of 26 genes linked to obesity including *LEP*, *LEPR*, *MC4R*, *NTRK2*, *PSCK1*, *POMC* and *SIM1*. They found two probands with severe early-onset obesity and high leptin levels which have two novel *LEPR* mutations in homozygosity.²⁷ Therefore, both whole-exome and whole-genome sequencing are important tools for genetic diagnosis of rare obesity forms.

One of the main challenges of WEC and WGS is the bioinformatics analysis of the massive amount of data that is generated. The employed analysis framework greatly varies among bioinformaticians, which can affect the ultimate result. Briefly, the resulting data is submitted for filtering using a database (usually, dbSNP), to remove common polymorphisms. Subsequently, variants are annotated by bioinformatics software, such as SIFT, PolyPhen, CONDEL, to highlight variants that affect coded proteins. Pathway analysis is performed, to assess the role of the variant in physiological pathways, and functional validation is conducted.

Technical limitations of WEC include the fact that 5% of the exome is not covered, and some mutations may be missed. Furthermore, WEC only covers protein coding regions which is less than 2% of the genome. Also, some areas composed by CG repeats are difficult to sequence, small insertions/deletions (indels) provide inaccurate data, and extended genes and pseudogenes are difficult to map. Extended structural variations are better detected by WGS, and CNVs are better assessed by chromosomal microarray. In NGS, often several potentially pathogenic variants are identified, which clinical significance is uncertain – those are called “variants of uncertain significance”. It is up to the clinical geneticist to assess whether variants identified by NGS are associated with the phenotype.

Of clinical relevance in the USA, the ACMG determines that laboratories conducting NGS must analyze and report mutations in 56 genes that have been associated with 24 Mendelian disorders. Besides reporting mutations that are known to cause the disease that led the patient to seek genetic diagnosis, laboratories may also report incidental or secondary results, that are not related to the main reason of genetic testing. To minimize distress to the patients and their families, it is recommended that patients attend pre-test counseling, when they are informed about the possibility of incidental findings, and choose whether they want to be informed or not (“opt-out”).

Negative results from the NGS do not exclude disease. Since those approaches and tools are in constant evolution, data can be reanalyzed after 6–12 months, when new genes, bioinformatics algorithms, and case reports are made available. If the WEC provides negative results, another alternative is to perform WGS, which more uniformly covers coding regions not well covered by WEC, and is able to detect structural rearrangements and CNVs (unlike WEC).¹³⁹

3.5.1. RVAT (rare-variant association tests)

While analyses from GWAS have successfully identified disease-causing variants in the past, they rely on the common disease, common variant hypothesis. Therefore, such analyses are not suitable

Table 2
Statistical quantifications of network analysis for monogenic obesity-related genes as implemented in Metacore algorithms.

Gene	Process ontology	Network nodes	Ontology P-value	Network z-score	Network P-value
<i>LRP2</i> , <i>LEP</i> , <i>LEPR</i> , <i>POMC</i>	Regulation of lipid metabolism	Leptin binding to leptin receptor (activation). Receptor binds and activates STAT5B Casein kinase II phosphorylate LRP2 (activation), LRP2 inhibits cytochrome c by binding.	5.524e ⁻⁴	143.67	8.48e ⁻⁷⁰
<i>LRP2</i> , <i>LEP</i> , <i>LEPR</i> , <i>POMC</i>	Response to nutrient levels	Leptin binding to leptin receptor (activation). Receptor binds and activates STAT5B Casein kinase II phosphorylate LRP2 (activation), LRP2 inhibits cytochrome c by binding.	1.011e ⁻¹²	143.67	8.48e ⁻⁷⁰
<i>LRP2</i> , <i>LEP</i> , <i>LEPR</i> , <i>POMC</i>	Regulation of carbohydrate metabolism	Leptin binding to leptin receptor (activation). Casein kinase II phosphorylate LRP2 (activation), LRP2 inhibits cytochrome c by binding.	1.106e ⁻³	143.67	8.48e ⁻⁷⁰
<i>LRP2</i> , <i>LEP</i> , <i>LEPR</i> , <i>POMC</i>	Regulation of protein metabolic process	Leptin binding to leptin receptor (activation). Receptor binds and activates STAT5B Casein kinase II phosphorylate LRP2 (activation), LRP2 inhibits cytochrome c by binding.	2.330e ⁻³⁰	143.67	8.48e ⁻⁷⁰
<i>LRP2</i>	Negative regulation of proteolysis	Casein kinase II phosphorylate LRP2 (activation), LRP2 inhibits cytochrome c by binding.	1.725e ⁻⁷	143.67	8.48e ⁻⁷⁰

P-values for process ontologies from the GeneGo database are given for the corresponding nodes in the network. Degree of enrichment for constructed network is calculated by z-score, based on number of genes from the input list. Significance of enrichment is given in Network P-value.

for rare variant studies, which could lead to missing heritability, especially given the hypothesis which states that disease causing alleles of large effect are likely to be of low frequency. Hence, in recent years, novel methods to perform rare-variant association tests (RVATs) have been developed. The most notable of these is the KBAC or Kernel Based Adaptive Cluster. Each rare variant within a particular gene is collapsed into multi-site genotypes. Thus, in brief, multi-site genotype frequency differences between cases and controls are calculated, as opposed to quantifying single variants only. This gene-based association test ensures that rare variants of potentially major effect are not completely discounted due to small individual effect size.¹⁴⁰

4. Network analysis of genes underpinning rare non-syndromic childhood forms of obesity

In order to better understand the potential mechanistic role of *LRP2* in morbid obesity, as previously described by our group, we ran analyses of pathways and network building algorithms from the Metacore GeneGo Software Suite from Thomson Reuters (version 6.29, build 68,613). Further details of the statistical analysis implemented in the various network-building algorithms can be found in supplementary materials and elsewhere.¹³⁵ These procedures allowed for the heuristic integration of maps and networks and corresponding ontologies for obesity related processes in order to quantitatively and qualitatively evaluate the biological role of *LRP2* in the context of all the other obesity-related genes described in Table 1.

The results of the aforementioned analyses are described in Fig. 1 and Table 2. As shown in Fig. 1, leptin binds to its receptor (LEPR), and subsequently STAT3, STAT5B and JAK2 bind to the intracellular domain of LEPR. Thereafter, JAK2 phosphorylates STAT3, STAT5B and ERK1/2, leading to three different pathways within this network. Phosphorylated STAT3 translocates into the nucleus to transcriptionally regulate (TR) c-Myc and POMC. The latter is then exported to the extracellular domain. Phosphorylated STAT5B also translocates to the nucleus to transcriptionally regulate Bcl-6, which in turn transcriptionally regulates casein kinase-2 (CK2) (where it is not known whether this has an activating or inhibitory effect). Thereafter, CK2 phosphorylates LRP2, which in turns binds to cytochrome-C (CYT-C) with an inhibitory effect. Phosphorylated ERK1/2 can phosphorylate c-Jun, which within the nucleus can transcriptionally regulate the

expression of CYT-C that subsequently translocates to the membrane. The pathway connecting ERK1/2 to CYT-C has been described, but was not significant with the “response to nutrient levels processes” (hence a question mark is shown in Fig. 1 linking these nodes). However, the fact that the proteins encoded by *LRP2* as well as the *LEPR* and its ligand are simultaneously linked (shown by these algorithms) to regulation of lipid storage and carbohydrate metabolism, means that they may have some potential pathway and network interactions in the biological processes and mechanisms of morbid obesity (Fig. 2).

The main processes in which *LRP2* was found associated to a subset of the genes causing monogenic forms of obesity are nutrient sensing processes and carbohydrate and lipid metabolism (Table 2). In Table 2, it is shown that there is evidence for the relatedness of *LRP2* with monogenic genes causing extreme forms of morbid obesity as quantified by the following statistical analyses described below. Firstly, the z-score of 143.67 of the constructed network yielded a P-value of 8.48×10^{-70} . Thus, this indicates that there is a significant degree of enrichment of the network with genes from the candidate input list. Hence, this network is potentially a highly accurate representation of the potential biological links and interactions of a subset of these candidate genes out of all those analyzed. The P-values for these three particular processes are 1.011×10^{-12} , 1.106×10^{-3} and 5.524×10^{-4} respectively (Table 2). Therefore, the probability that these nodes within the network (including proteins encoded by *LRP2* as well as *LEP*, *LEPR* and *POMC*) are associated with these processes simply due to chance (according to the hypergeometric distribution calculation under the null hypothesis) is considerably low. Thus, based on this evidence, one can postulate that a mutation in the *LRP2* gene can alter those mentioned processes and pathways, which may have substantial implications in morbid obesity.

5. Genetic diagnosis applied for patient suspected of NEOSO

Monogenic obesity syndromes and nonsyndromes are rare and mainly result in severe early onset-obesity. These disorders may occur due to chromosomal abnormalities and/or highly penetrant genetic variants in critical genes for regulation of energy intake and expenditure.¹⁴¹ Recently, a clinical practice guideline was published suggesting how to proceed with patients suspected of Mendelian forms of obesity.¹⁴² Specialists have suggested that all assessment of




Fig. 2. Diagrammatic representation of network analyses for monogenic morbid obesity-related genes. This diagram shows the involvement of a subset of the input gene list from Table 1 (red font) in a network comprising different compartments: extracellular, membrane, cytoplasm and nucleus. Solid arrows depict activation and broken arrows show inhibition. Thin solid arrows depict unknown effect (i.e. it is uncertain whether there is inhibition or activation). The question marks “?” depict interactions that were described in other processes but that did not show relatedness to the processes mentioned in Table 2 as they are seemingly not thoroughly annotated within the Metacore GeneGo database. However, they are part of the same network and may have relevant interactions as shown in this figure. The abbreviations “TR”, “B” and “P” indicate transcriptional regulation, binding and phosphorylation, respectively.

children and adults with severe obesity should be careful, since it may help to guide the disorder diagnosis.

Based on the practice guideline, physical examination and medical history about the patient is required to establish the age of obesity onset, presence of hyperphagia, developmental delay and/or dysmorphic features. In addition, family history should be obtained to identify the consanguineous relationships, other family cases with severe obesity/bariatric surgery and the ethnic and geographical origin of the family.

Abnormalities in the medical history and/or the physical examination may be a potential endocrine, genetic or hypothalamic obesity disorders. Patients with severe early onset obesity (before 5 years age), neurodevelopmental abnormalities and/or severe hyperphagia are susceptible to the Mendelian form of obesity and genetic testing should be performed. When these patients have a development delay, karyotype and DNA methylation studies are a useful strategy for identifying Prader-Willi Syndrome. Patients with negative results and additional features (retinal dystrophy, photophobia or nystagmus) could indicate Bardet-Biedl syndrome, Alström syndrome or Tub deficiency. However, patients with negative results and without these additional features could be tested for Albright Hereditary Osteodystrophy, BDNF, Trkb e SIM1 deficiency.

Additionally, severe obesity patients without development delays should have leptin, proinsulin and insulin levels assessed. When these subjects have decreased or undetectable leptin levels, it might indicate LEP deficiency. Nevertheless, elevated ratio of proinsulin/insulin (mature) levels suggest PCSK1 deficiency. Finally, patients with normal levels of those hormones may be genetically tested to different deficiencies, such as LEP, LEPR, POMC, MC4R, SH2B1 and KSR2.^{142,143}

Importantly, consideration should be given to the ethical aspects of genetic testing and its implications. Pretest counseling is warranted, to establish realistic expectations for unveiling a causative gene variant, and to make patients and families aware that a positive result

is unlikely to change the clinical management, given the lack of available targeted therapies. Also, the discovery of incidental findings unrelated to the reason for testing might create additional stress to the patient, and should be clearly disclosed. Furthermore, the implications of a positive finding to biological relatives should be discussed with the patient, as well as the fact that the interpretation of a positive result should be correlated with clinical findings. Finally, although genetic testing costs, particularly of NGS, are decreasing, widespread use of these diagnostic tools still adds financial burden to patients and the healthcare system.

6. Current clinical approach in non-syndromic monogenic obesity

Promising approaches based on high-throughput next-generation sequencing technologies have the potential to guide a robust genetic diagnosis and identify new genes and pathways in the future. Molecular diagnosis of monogenic obesity is important to the patients and their families, since the clinicians could manage the patient appropriately and provide the genetic counseling.^{143,144} The management of these patients based on lifestyle and behavioral modification appears to not be so efficient long-term, since they are relatively resistant to losing and/or maintaining the weight loss.^{142,145}

Bariatric surgery is an effective therapy for severe obesity; however, the efficacy in patients with monogenic forms of obesity has extremely limited data and is still up for debate.^{142,146} Adult patients with heterozygous MC4R mutations who were submitted to Roux-en-Y gastric bypass had an effect of excess weight loss compared to a cohort of controls without MC4R mutations. Those patients were able to lose about 60% of excess weight after the surgery.¹⁴⁷ In addition, four adolescents with heterozygous MC4R mutations were evaluated in a restrictive bariatric surgery, in which three underwent laparoscopic adjustable gastric banding and one was submitted to vertical sleeve gastrectomy. The four patients and their




Fig. 3. Sites of involvement of the various genes associated with obesity and the physiological pathways affected by them. Schematic representation of the sites of action of the proteins expressed by the genes associated with obesity, and the pathways affected by them. LEP: leptin; LEPR: leptin receptor; PCSK1: proprotein convertase subtilisin/kexin type 1; POMC: pro-opiomelanocortin; TUB: tubby bipartite transcription factor; SH2B1: Src homology 2 B adapter protein 1; MC4R: melanocortin-4 receptor; MRP2: melanocortin 2 receptor accessory proteins 2; KSR2: kinase suppressor of ras 2; SIM1: single-minded homolog 1; BDNF: brain-derived neurotrophic factor; NTRK2: neurotrophic tyrosine kinase receptor type 2; LRP2: low-density lipoprotein receptor 2; FFA: free fatty acids.

matched controls had a similar rate of absolute weight loss, BMI change and percentage of excess weight loss at 1 year, postbariatric surgery.¹⁴⁸ In contrast to the above findings, Aslan et al.¹⁴⁷ have reported an unsuccessful case of weight loss in an adolescent patient (18.7-year old) who is compound heterozygous for two loss of function MC4R mutations. Those findings suggest the complete functional loss of MC4R may render the bariatric surgery an ineffective procedure to lose weight in the long-term. Unexpectedly, Bonnefond et al.¹⁴⁹ found that patients carrying gain of function MC4R mutations had higher risk of reoperation. Therefore, more studies about the effect of bariatric surgery in patients with MC4R mutations are necessary.

Nowadays, specific treatment is available for patients with leptin deficiency. In these cases, adults and children are treated with subcutaneous injection of recombinant human leptin, reducing food intake and weight. Furthermore, the administration of metreleptin improves most of the metabolic and endocrine dysfunctions seen in these patients.^{83,133,150} Unfortunately, leptin treatment is inefficient in LEPR-deficient patients, since their receptors are non-functional. Additionally, there is no specific treatment for other human cases of non-syndromic monogenic obesity. The physiological systems that control appetite and regulate body weight may harbour numerous targets for anti-obesity drugs. Thus, researchers are developing new molecules for pharmacological obesity treatment which act on the leptin-melanocortin pathway; however it is still in clinical trials.¹⁵¹

7. Conclusion

Clearly, obesity is a complex disease influenced by different factors. In most cases, the individual variability of becoming obese is due to many gene variants of minor effect. However, several studies have reported patients with severe early-onset obesity and endocrine

dysfunctions caused by single gene mutations that disrupt the development of the hypothalamus and leptin-melanocortin pathway (Fig. 3). In the past few years, several molecular approaches and technologies were developed and have provided a small understanding of the genetic background of obesity. New genetic tools, such as whole-genome/exome sequencing, have been identifying novel variants and genes associated with common and rare forms of obesity. Those high-throughput DNA sequencing technologies have increasingly been used in the clinics, and their contribution to the development of new therapeutic targets for Mendelian obesity, and to the improvement quality of life remains to be determined.

References

- World Health Organization. Childhood overweight and obesity. Available at: <http://www.who.int/dietphysicalactivity/childhood/en/2015>. [Accessed 11 March 2017].
- Centers for Disease Control and Prevention. Youth risk behavior surveillance—United States, 2011. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/ss6104a1.htm2012>. [Accessed 12 March 2017].
- Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. *JAMA*. 2014;311:806–14. <http://dx.doi.org/10.1001/jama.2014.732>.
- Rosaneli CF, Baena CP, Auler F, Nakashima ATA, Netto-Oliveira ER, Oliveira AB, et al. Elevated blood pressure and obesity in childhood: a cross-sectional evaluation of 4,609 schoolchildren. *Arq Bras Cardiol*. 2014;238–44. <http://dx.doi.org/10.5935/abc.20140104>.
- World Health Organization. Obesity and overweight. Available at: <http://www.who.int/mediacentre/factsheets/fs311/en/2016>. [Accessed 21 December 2016].
- World Health Organization. Global status report on noncommunicable diseases: World Health Organization. Available at: http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf?ua=1 2014. [Accessed 13 March 2017].
- Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2014;384:766–81. [http://dx.doi.org/10.1016/S0140-6736\(14\)60460-8](http://dx.doi.org/10.1016/S0140-6736(14)60460-8).
- Wabitsch M, Moss A, Kromeyer-Hauschild K. Unexpected plateauing of childhood obesity rates in developed countries. *BMC Med*. 2014;12:17. <http://dx.doi.org/10.1186/1741-7015-12-17>.
- Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH. Predicting obesity in young adulthood from childhood and parental obesity. *N Engl J Med*. 1997;337:869–73. <http://dx.doi.org/10.1056/NEJM199709253371301>.
- Kumar S, Kelly AS. Review of childhood obesity. *Mayo Clin Proc*. 2017;1–15. <http://dx.doi.org/10.1016/j.mayocp.2016.09.017>.
- Sahoo K, Sahoo B, Choudhury A, Sufi N, Kumar R, Bhadoria AS. Childhood obesity: causes and consequences. *J Fam Med Prim Care*. 2015;4:187. <http://dx.doi.org/10.4103/2249-4863.154628>.
- Sawyer MG, Harchak T, Wake M, Lynch J. Four-year prospective study of BMI and mental health problems in young children. *Pediatrics*. 2011. [Retrieved from <http://pediatrics.aappublications.org/content/early/2011/09/15/peds.2010-3132.abstract>].
- Strauss RS. Childhood obesity and self-esteem. *Pediatrics*. 2000;105:e15 LP-e15. [Retrieved from <http://pediatrics.aappublications.org/content/105/1/e15.abstract>].
- Berkowitz RI, Daniels S. Now is the time to improve access and healthcare systems for childhood obesity treatment. *Obesity*. 2017;25:13–4. <http://dx.doi.org/10.1002/oby.21740>.
- Orsi CM, Hale DE, Lynch JL. Pediatric obesity epidemiology. *Curr Opin Endocrinol Diabetes Obes*. 2011;18. [Retrieved from http://journals.lww.com/co-endocrinology/Fulltext/2011/02000/Pediatric_obesity_epidemiology.5.aspx].
- Lynch BA, Finney Rutten LJ, Jacobson RM, Kumar S, Elrashidi MY, Wilson PM, et al. Health care utilization by body mass index in a pediatric population. *Acad Pediatr*. 2015;15:644–50. <http://dx.doi.org/10.1016/j.acap.2015.08.009>.
- Trasande L, Chatterjee S. The impact of obesity on health service utilization and costs in childhood. *Obesity*. 2009;17:1749–54. <http://dx.doi.org/10.1038/oby.2009.67>.
- Kasman M, Hammond RA, Werman A, Mack-Crane A, McKinnon RA. An in-depth look at the lifetime economic cost of obesity. *Brookings Institute*. 2015.
- Lakshman R, Elks CE, Ong KK. Childhood obesity. *Circulation*. 2012;126:1770–9. [Retrieved from <http://circ.ahajournals.org/content/126/14/1770.abstract>].
- Xia Q, Grant SF. The genetics of human obesity. *Ann N Y Acad Sci*. 2013;1281:178–90. <http://dx.doi.org/10.1111/nyas.12020>.
- Farooqi IS, O'Rahilly S. New advances in the genetics of early onset obesity. *Int J Obes (Lond)*. 2005;29:1149–52. <http://dx.doi.org/10.1038/sj.ijo.0803056>.
- Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature*. 2015;518:197–206. <http://dx.doi.org/10.1038/nature14177>.
- O'Rahilly S. Human genetics illuminates the paths to metabolic disease. *Nature*. 2009;462:307–14. <http://dx.doi.org/10.1038/nature08532>.
- Paz-Filho G, Mastrorandi C, Delibasi T, Wong M, Licinio J. Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy. *Arq Bras Endocrinol Metabol*. 2010;54:690–7. <http://dx.doi.org/10.1590/S0004-27302010000800005>.

25. Montague CT, Farooqi IS, Wareham NJ, Sewter CP, Cheetham CH, Earley AR, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. *Nature*. 1997;387:903–8, <http://dx.doi.org/10.1038/43185>.
26. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. *Nature*. 1998;392:398–401.
27. Saeed S, Bonnefond A, Manzoor J, Philippe J, Durand E, Arshad M, et al. Novel LEPR mutations in obese Pakistani children identified by PCR-based enrichment and next generation sequencing. *Obesity (Silver Spring)*. 2014;22:1112–7, <http://dx.doi.org/10.1002/oby.20667>.
28. Farooqi SI, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. *N Engl J Med*. 2007;356:237–47, <http://dx.doi.org/10.1056/NEJMoa063988>. Clinical.
29. Farooqi IS, Volders K, Stanhope R, Heuschkel R, White A, Lank E, et al. Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3. *J Clin Endocrinol Metab*. 2007;92:3369–73, <http://dx.doi.org/10.1210/jc.2007-0687>.
30. Kühnen P, Clement K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. *N Engl J Med*. 2016;375:240–6, <http://dx.doi.org/10.1056/NEJMoa1512693>.
31. Borman AD, Pearce LR, Mackay DS, Nagel-Wolfrum K, Davidson AE, Henderson R, et al. A homozygous mutation in the TUB gene associated with retinal dystrophy and obesity. *Hum Mutat*. 2014;35:289–93, <http://dx.doi.org/10.1002/humu.22482>.
32. Doche ME, Henning E, Cline JM, Dale A, Cheetham T, Argetsinger LS, et al. Human SH2B1 mutations are associated with maladaptive behaviors and obesity. *J Clin Invest*. 2012;122:4732–6, <http://dx.doi.org/10.1172/JCI62696>.4732.
33. Rui L. SH2B1 regulation of energy balance, body weight, and glucose metabolism. *World J Diabetes*. 2014;5:511–26, <http://dx.doi.org/10.4239/wjdv5.i4.511>.
34. Doulla M, McIntyre AD, Hegele RA, Gallego PH. A novel MC4R mutation associated with childhood-onset obesity: a case report. *Paediatr Child Health*. 2014;19:515–8. [<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276379/>].
35. Farooqi IS, Keogh JM, Yeo GSH, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. *N Engl J Med*. 2003;348:1085–95, <http://dx.doi.org/10.1056/NEJMoa022050>.
36. Melchior C, Schulz A, Windholz J, Kiess W, Schneberg T, Krmer A. Clinical and functional relevance of melanocortin-4 receptor variants in obese german children. *Horm Res Paediatr*. 2012;78:237–46, <http://dx.doi.org/10.1159/000343816>.
37. Farooqi SI. Genetic, molecular and physiological mechanisms involved in human obesity: society for endocrinology medal lecture 2012. *Clin Endocrinol (Oxf)*. 2015;82:23–8, <http://dx.doi.org/10.1111/cen.12588>.
38. Asai M, Ramachandrapa S, Joachim M, Shen Y, Zhang R, Nuthalapati N, et al. Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity. *Science*. 2013;341:275–8, <http://dx.doi.org/10.1126/science.1233000>.
39. Schonnop L, Kleinau G, Herrfurth N, Volckmar A-L, Cetindag C, Müller A, et al. Decreased melanocortin-4 receptor function conferred by an infrequent variant at the human melanocortin receptor accessory protein 2 gene. *Obesity*. 2016;24:1976–82, <http://dx.doi.org/10.1002/oby.21576>.
40. Pearce LR, Atanassova N, Banton MC, Bottomley B, Van Der Klaauw AA, Revelli JP, et al. KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular fuel oxidation. *Cell*. 2013;155:765–77, <http://dx.doi.org/10.1016/j.cell.2013.09.058>.
41. Costanzo-Garvey DL, Pfluger PT, Dougherty MK, Stock JL, Boehm M, Chaika O, et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. *Cell Metab*. 2009;10:366–78, <http://dx.doi.org/10.1016/j.cmet.2009.09.010>.
42. Ramachandrapa S, Gorrigan RJ, Clark AJL, Chan LF. The melanocortin receptors and their accessory proteins. *Front Endocrinol*. 2013;4:1–8, <http://dx.doi.org/10.3389/fendo.2013.00009>.
43. Holder JL, Zhang L, Kublaoui BM, DiLeone RJ, Oz OK, Bair CH, et al. Sim1 gene dosage modulates the homeostatic feeding response to increased dietary fat in mice. *Am J Physiol Endocrinol Metab*. 2004;287:E105–3, <http://dx.doi.org/10.1152/ajpendo.00446.2003>.
44. Gray J, Yeo GSH, Cox JJ, Morton J, Adlam A-LR, Keogh JM, et al. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. *Diabetes*. 2006;55:3366–71, <http://dx.doi.org/10.2337/db06-0550>.
45. Yeo GSH, Connie Hung C-C, Rochford J, Keogh J, Gray J, Sivaramkrishnan S, et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. *Nat Neurosci*. 2004;7:1187–9, <http://dx.doi.org/10.1038/nn1336>.
46. Paz-Filho G, Boguszewski MCS, Mastronardi CA, Patel HR, Johar AS, Chuah A, et al. Whole exome sequencing of extreme morbid obesity patients: translational implications for obesity and related disorders. *Genes*. 2014;5:709–25, <http://dx.doi.org/10.3390/genes5030709>.
47. Skinner AC, Skelton JA. Prevalence and trends in obesity and severe obesity among children in the United States, 1999–2012. *JAMA Pediatr*. 2014;168:561–6, <http://dx.doi.org/10.1001/jamapediatrics.2014.21>.
48. Garnett SP, Baur LA, Jones AMD, Hardy LL. Trends in the prevalence of morbid and severe obesity in Australian children aged 7–15 years, 1985–2012. *PLoS One*. 2016;11:e0154879, <http://dx.doi.org/10.1371/journal.pone.0154879>.
49. Sandholt CH, Grarup N, Pedersen O, Hansen T. Genome-wide association studies of human adiposity: zooming in on synapses. *Mol Cell Endocrinol*. 2015;418:90–100, <http://dx.doi.org/10.1016/j.mce.2015.09.029>.
50. Yazdi FT, Clew SM, Meyre D. Obesity genetics in mouse and human: back and forth, and back again. *PeerJ*. 2015;3:e856, <http://dx.doi.org/10.7717/peerj.856>.
51. van der Klaauw AA, Farooqi IS. The hunger genes: pathways to obesity. *Cell*. 2015;161:119–32, <http://dx.doi.org/10.1016/j.cell.2015.03.008>.
52. Walley AJ, Asher JE, Froguel P. The genetic contribution to non-syndromic human obesity. *Nat Rev Genet*. 2009;10:431–42, <http://dx.doi.org/10.1038/nrg2594>.
53. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat Genet*. 2010;42:937–48, <http://dx.doi.org/10.1038/ng.686>.
54. McAllister EJ, Dhurandhar NV, Keith SW, Aronne LJ, Barger J, Baskin M, et al. Ten putative contributors to the obesity epidemic. *Crit Rev Food Sci Nutr*. 2009;49:868–913, <http://dx.doi.org/10.1080/10408390903372599>.
55. Yang W, Kelly T, He J. Genetic epidemiology of obesity. *Epidemiol Rev*. 2007;29:49–61, <http://dx.doi.org/10.1093/epirev/mxm004>.
56. Bouchard C, Tremblay A, Després J-P, Nadeau A, Lupien PJ, Thériault G, et al. The response to long-term overfeeding in identical twins. *N Engl J Med*. 1990;322:1477–82, <http://dx.doi.org/10.1056/NEJM199005243222101>.
57. Bouchard C, Tremblay A, Després J-P, Thériault G, Nadeau A, Lupien PJ, et al. The response to exercise with constant energy intake in identical twins. *Obes Res*. 1994;2:400–10, <http://dx.doi.org/10.1002/j.1550-8528.1994.tb00087.x>.
58. Stunkard AJ, Sørensen TIA, Hanis C, Teasdale TW, Chakraborty R, Schull WJ, et al. An adoption study of human obesity. *N Engl J Med*. 1986;314:193–8, <http://dx.doi.org/10.1056/NEJM198601233140401>.
59. Huvonen H, Dubern B, Clément K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. *Obes Facts*. 2016;9:158–73, <http://dx.doi.org/10.1159/000445061>.
60. Albuquerque D, Stice E, Rodríguez-López R, Manco L, Nóbrega C. Current review of genetics of human obesity: from molecular mechanisms to an evolutionary perspective. *Mol Genet Genomics*. 2015;290:1991, <http://dx.doi.org/10.1007/s00438-015-1015-9>.
61. Bell CG, Walley AJ, Froguel P. The genetics of human obesity. *Nat Rev Genet*. 2005;6:221–34, <http://dx.doi.org/10.1038/nrg1556>.
62. Larder R, Lim CT, Coll AP. Chapter 6 - genetic aspects of human obesity. In: Fliers Eric, Korbonits Márta, Romijn Johannes A, eds. *Clinical neuroendocrinology*, Vol. 124. Elsevier; 2014. p. 93–106, <http://dx.doi.org/10.1016/B978-0-444-59602-4.00006-X>.
63. Anand BK, Brobeck JR. Hypothalamic control of food intake in rats and cats. *Yale J Biol Med*. 1951;24:123–40. [Retrieved from <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2599116/>].
64. Hetherington AW, Ranson SW. Hypothalamic lesions and adiposity in the rat. *Anat Rec*. 1940;78:149–72, <http://dx.doi.org/10.1002/ar.1090780203>.
65. Daoussi C, Dunn AJ, Foy PM, MacFarlane IA, Pinkney JH. Endocrine and neuroanatomic features associated with weight gain and obesity in adult patients with hypothalamic damage. *Am J Med*. 2005;118:45–50, <http://dx.doi.org/10.1016/j.amjmed.2004.06.035>.
66. Vetter ML, Faulconbridge LF, Webb VL, Wadden TA. Behavioral and pharmacologic therapies for obesity. *Nat Rev Endocrinol*. 2010;6:578–88, <http://dx.doi.org/10.1038/nrendo.2010.121>.
67. Ranadive SA, Vaisse C. Lessons from extreme human obesity: monogenic disorders. *Endocrinol Metab Clin North Am*. 2008;37:733–51, <http://dx.doi.org/10.1016/j.ecl.2008.07.003>.
68. Romieu I, Dossus I, Barquera S, Blottière HM, Franks PW, Gunter M, et al. Energy balance and obesity: what are the main drivers? *Cancer Causes Control*. 2017;28:247–58, <http://dx.doi.org/10.1007/s10552-017-0869-z>.
69. Smith AL, Funder JW. Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. *Endocr Rev*. 1988;9:159–79, <http://dx.doi.org/10.1210/edrv-9-1-159>.
70. Tao Y-X. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. *Mol Cell Endocrinol*. 2005;239:1–14, <http://dx.doi.org/10.1016/j.mce.2005.04.012>.
71. Cone RD. Anatomy and regulation of the central melanocortin system. *Nat Neurosci*. 2005;8:571–8. [Retrieved from <http://dx.doi.org/10.1038/nn1455>].
72. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. *Nature*. 2006;443:289–95. [Retrieved from <http://dx.doi.org/10.1038/nature05026>].
73. Sutton AK, Myers MG, Olson DP. The role of PVH circuits in leptin action and energy balance. *Annu Rev Physiol*. 2016;78:207–21, <http://dx.doi.org/10.1146/annurev-physiol-021115-105347>.
74. Chesni A, Grant SFA. The genetics of pediatric obesity. *Trends Endocrinol Metab*. 2015;26:711–21, <http://dx.doi.org/10.1016/j.tem.2015.08.008>.
75. Savona-Ventura C, Savona-Ventura S. The inheritance of obesity. *Best Pract Res Clin Obstet Gynaecol*. 2015;29:300–8, <http://dx.doi.org/10.1016/j.bpobgyn.2014.07.023>.
76. Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the mouse house. *J Hered*. 1950;41:315–7, <http://dx.doi.org/10.1093/oxfordjournals.jhered.a106072>.
77. Coleman DL. Effects of parabiosis of obese with diabetes and normal mice. *Diabetologia*. 1973;9:294–8, <http://dx.doi.org/10.1007/BF01221857>.
78. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. *Nature*. 1994, <http://dx.doi.org/10.1038/372425a0>.
79. Gibson WT, Farooqi IS, Moreau M, DePaoli AM, Lawrence E, O'Rahilly S, et al. Congenital leptin deficiency due to homozygosity for the Δ133G mutation: report of another case and evaluation of response to four years of leptin therapy. *J Clin Endocrinol Metab*. 2004;89:4821–6, <http://dx.doi.org/10.1210/jc.2004-0376>.
80. Saeed S, Bonnefond A, Manzoor J, Shabir F, Ayesha H, Philippe J, et al. Genetic variants in LEP, LEPR, and MC4R explain 30% of severe obesity in children from a consanguineous population. *Obesity (Silver Spring)*. 2015;23:1687–95, <http://dx.doi.org/10.1002/oby.21142>.
81. Paz-Filho G, Mastronardi CA, Licinio J. Leptin treatment: facts and expectations. *Metabolism*. 2015;64:146–56, <http://dx.doi.org/10.1016/j.metabol.2014.07.014>.
82. Paz-Filho G, Wong ML, Licinio J. Ten years of leptin replacement therapy. *Obes Rev*. 2011;12:315–23, <http://dx.doi.org/10.1111/j.1467-789X.2010.00840.x>.
83. Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O'Kirwan F, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. *Proc Natl Acad Sci*. 2004;101:4531–6, <http://dx.doi.org/10.1073/pnas.0308767101>.

84. Wabitsch M, Funcke J-B, Lennerz B, Kuhnle-Krahl U, Lahr G, Debatin K-M, et al. Biologically inactive leptin and early-onset extreme obesity. *N Engl J Med*. 2015;372:48–54. <http://dx.doi.org/10.1056/NEJMoa1406653>.
85. Gill R, Cheung YH, Shen Y, Lanzano P, Mirza NM, Ten S, et al. Whole-exome sequencing identifies novel LEPR mutations in individuals with severe early-onset obesity. *Obesity (Silver Spring)*. 2014;22:576–84. <http://dx.doi.org/10.1002/oby.20492>.
86. Clark AJL. 60 YEARS OF POMC: the proopiomelanocortin gene: discovery, deletion and disease. *J Mol Endocrinol*. 2016;56:T27–37. <http://dx.doi.org/10.1530/JME-15-0268>.
87. Clément K, Dubern B, Mencarelli M, Czernichow P, Ito S, Wakamatsu K, et al. Unexpected endocrine features and normal pigmentation in a young adult patient carrying a novel homozygous mutation in the POMC gene. *J Clin Endocrinol Metabol*. 2008;93:4955–62. <http://dx.doi.org/10.1210/jc.2008-1164>.
88. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. *Nat Genet*. 1998;19:155–7. <http://dx.doi.org/10.1038/509>.
89. Farooqi IS, Drop S, Clements A, Keogh JM, Biernacka J, Lowenbein S, et al. Heterozygosity for a POMC-null mutation and increased obesity risk in humans. *Diabetes*. 2006;55:2549–53. <http://dx.doi.org/10.2337/db06-0214>.
90. Mendiratta MS, Yang Y, Balazs AE, Willis AS, Eng CM, Karaviti LP, et al. Early onset obesity and adrenal insufficiency associated with a homozygous POMC mutation. *Int J Pediatr Endocrinol*. 2011;2011:5. <http://dx.doi.org/10.1186/1687-9856-2011-5>.
91. Samuels ME, Gallo-Payet N, Pinard S, Hasselmann C, Magne F, Patry L, et al. Bioinactive ACTH causing glucocorticoid deficiency. *J Clin Endocrinol Metabol*. 2013;98:736–42. <http://dx.doi.org/10.1210/jc.2012-3199>.
92. Müller TD, Tschöp MH, O'Rahilly S. Metabolic precision medicines: curing POMC deficiency. *Cell Metab*. 2016;24:194–5. <http://dx.doi.org/10.1016/j.cmet.2016.07.006>.
93. Frank GR, Fox J, Candela N, Jovanovic Z, Bochukova E, Levine J, et al. Severe obesity and diabetes insipidus in a patient with PCSK1 deficiency. *Mol Genet Metab*. 2013;110:191–4. <http://dx.doi.org/10.1016/j.ymgme.2013.04.005>.
94. Hoshino A, Lindberg I. Peptide biosynthesis: prohormone convertases 1/3 and 2. *Colloq Ser Neuropeptides*. 2012;1:1–112. <http://dx.doi.org/10.4199/C0050ED1V01Y201112NPE001>.
95. Valette M, Bellisle F, Carette C, Poitou C, Dubern B, Paradis G, et al. Eating behaviour in obese patients with melanocortin-4 receptor mutations: a literature review. *Int J Obes (Lond)*. 2013;37:1027–35. <http://dx.doi.org/10.1038/ijo.2012.169>.
96. Jackson RS, Creemers JWM, Farooqi IS, Raffin-Sanson ML, Varro A, Dockray GJ, et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. *J Clin Invest*. 2003;112:1550–60. <http://dx.doi.org/10.1172/JCI200318784>.
97. Jackson RS, Creemers JWM, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. *Nat Genet*. 1997;16:303–6.
98. Martin MG, Solorzano-Vargas RS, Wang J, Avitzur Y, Bandsma R, Sokollik C, et al. Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort. *Gastroenterology*. 2013;145:138–48. <http://dx.doi.org/10.1016/j.freeradbiomed.2008.10.025>.
99. Philippe J, Stijnen P, Meyre D, De Graeve F, Thuillier D, Delplanque J, et al. A nonsense loss-of-function mutation in PCSK1 contributes to dominantly inherited human obesity. *Int J Obes (Lond)*. 2015;39:1–30. <http://dx.doi.org/10.1038/ijo.2014.96>.
100. Kleyn PW, Fan W, Kovats SG, Lee JJ, Pulido JC, Wu Y, et al. Identification and characterization of the mouse obesity gene *tubby*: a member of a novel gene family. *Cell*. 1996;85:281–90. [http://dx.doi.org/10.1016/S0092-8674\(00\)81104-6](http://dx.doi.org/10.1016/S0092-8674(00)81104-6).
101. Prada PO, Quaresma PGF, Caricilli AM, Santos AC, Guadagnini D, Morari J, et al. Tub has a key role in insulin and leptin signaling and action in vivo in hypothalamic nuclei. *Diabetes*. 2013;62:137–48. <http://dx.doi.org/10.2337/db11-1388>.
102. Tapia-Arancibia L, Rage F, Givalois L, Arancibia S. Physiology of BDNF: focus on hypothalamic function. *Front Neuroendocrinol*. 2004;25:77–107. <http://dx.doi.org/10.1016/j.ynfe.2004.04.001>.
103. Gray J, Yeo G, Hung C, Keogh J, Clayton P, Banerjee K, et al. Functional characterization of human NTRK2 mutations identified in patients with severe early-onset obesity. *Int J Obes (Lond)*. 2007;31:359–64. <http://dx.doi.org/10.1038/sj.ijo.0803390>.
104. Holder JL, Butte NF, Zinn AR. Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. *Hum Mol Genet*. 2000;9:101–8. <https://doi.org/10.1093/hmg/9.1.101>.
105. Ramachandrapa S, Raimondo A, Cali AMG, Keogh JM, Henning E, Saeed S, et al. Rare variants in single-minded 1 (SIM1) are associated with severe obesity. *J Clin Invest*. 2013;123:1–9. <http://dx.doi.org/10.1172/JCI68016DS1>.
106. Zegers D, Beckers S, Hendrickx R, Van Camp JK, de Craemer V, Verrijken A, et al. Mutation screen of the SIM1 gene in pediatric patients with early-onset obesity. *Int J Obes (Lond)*. 2014;38:1000–4. <http://dx.doi.org/10.1038/ijo.2013.188>.
107. Dores RM, Liang L, Davis P, Thomas AL, Petko B. Melanocortin receptors: evolution of ligand selectivity for melanocortin peptides. *J Mol Endocrinol*. 2016;56:T119–33. <http://dx.doi.org/10.1530/JME-15-0292>.
108. Stanikova D, Surova M, Ticha L, Petrasova M, Virgova D, Huckova M, et al. Melanocortin-4 receptor gene mutations in obese slovak children. *Physiol Res*. 2015;64:883–90. <http://dx.doi.org/10.1073/pnas.0703993104>.
109. Dubern B, Clément K, Pelloux V, Froguel P, Girardet JP, Guy-Grand B, et al. Mutational analysis of melanocortin-4 receptor, agouti-related protein, and alpha-melanocyte-stimulating hormone genes in severely obese children. *J Pediatr*. 2001;139:204–9. <http://dx.doi.org/10.1067/mpd.2001.116284>.
110. Miraglia Del Giudice E, Cirillo G, Nigro V, Santoro N, D'Urso L, Raimondo P, et al. Low frequency of melanocortin-4 receptor (MC4R) mutations in a Mediterranean population with early-onset obesity. *Int J Obes Relat Metab Disord*. 2002;26:647–51. <http://dx.doi.org/10.1038/sj.ijo.0801983>.
111. Polverelli M, Teoule R, Gamma irradiation of cytosine in an aerated aqueous solution. II. Kinetic study of the formation of the radiolysis products of cytosine resulting from the deamination pathway. *Z Naturforsch C*. 2014;29:16–8. [Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/4276379>].
112. Xi B, Chandak GR, Shen Y, Wang Q, Zhou D. Association between common polymorphism near the MC4R gene and obesity risk: a systematic review and meta-analysis. *PLoS One*. 2012;7:e45731. <http://dx.doi.org/10.1371/journal.pone.0045731>.
113. Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G, et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. *J Clin Invest*. 2000;106:271–9. <http://dx.doi.org/10.1172/JCI9397>.
114. Vollbach H, Brandt S, Lahr G, Denzer C, Von Schnurbein J, Debatin K-M, et al. Prevalence and phenotypic characterization of MC4R variants in a large pediatric cohort. *International Journal of Obesity*. Nature Publishing Group; 2016. <http://dx.doi.org/10.1038/ijo.2016.161>.
115. Chen KY, Muniyappa R, Abel BS, Mullins KP, Staker P, Brychta RJ, et al. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. *J Clin Endocrinol Metab*. 2015;100:1639–45. <http://dx.doi.org/10.1210/jc.2014-4024>.
116. René P, Le Gouill C, Pogozheva ID, Lee G, Mosberg HI, Farooqi IS, et al. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity. *J Pharmacol Exp Ther*. 2010;335:520–32. <http://dx.doi.org/10.1124/jpet.110.172098>.
117. Chan LF, Webb TR, Chung T-T, Meiraidou E, Cooray SN, Guasti L, et al. MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family. *Proc Natl Acad Sci U S A*. 2009;106:6146–51. <http://dx.doi.org/10.1073/pnas.0809918106>.
118. Pearce LR, Joe R, Doche ME, Su HW, Keogh JM, Henning E, et al. Functional characterization of obesity-associated variants involving the α and β isoforms of human SH2B1. *Endocrinology*. 2014;155:3219–26. <http://dx.doi.org/10.1210/en.2014-1264>.
119. Bochukova EG, Huang N, Keogh J, Henning E, Purmann C, Blaszczyk K, et al. Large, rare chromosomal deletions associated with severe early-onset obesity. *Nature*. 2010;463:666–70. <http://dx.doi.org/10.1038/nature08689>.
120. Revelli J-P, Smith D, Allen J, Jeter-Jones S, Shadoan MK, Desai U, et al. Profound obesity secondary to hyperphagia in mice lacking kinase suppressor of ras 2. *Obesity (Silver Spring)*. 2011;19:1010–8. <http://dx.doi.org/10.1038/oby.2010.282>.
121. Bowden DW, Sale M, Howard TD, Qadri A, Spray BJ, Rothschild CB, et al. Linkage of genetic markers on human chromosomes 20 and 12 to NIDDM in Caucasian sib pairs with a history of diabetic nephropathy. *Diabetes*. 1997;46:882–6. <http://dx.doi.org/10.2337/diab.46.5.882>.
122. Li WD, Dong C, Li D, Zhao H, Price RA. An obesity-related locus in chromosome region 12q23-24. *Diabetes*. 2004;53:812–20. <http://dx.doi.org/10.2337/diab.53.3.812>.
123. Gil SY, Youn B-S, Byun K, Huang H, Namkoong C, Jang P, et al. Clusterin and LRPI are critical components of the hypothalamic feeding regulatory pathway. *Nat Commun*. 2013;4:1862–9. <http://dx.doi.org/10.1038/ncomms2896>.
124. Hu H, Roach JC, Coon H, Guthery SL, Voelkerding KV, Margraf RL, et al. A unified test of linkage analysis and rare-variant association for analysis of pedigree sequence data. *Nat Biotechnol*. 2014;32:663–9. [Retrieved from <http://dx.doi.org/10.1038/nbt.2895>].
125. El-Sayed Moustafa JS, Froguel P. From obesity genetics to the future of personalized obesity therapy. *Nat Rev Endocrinol*. 2013;9:402–13. <http://dx.doi.org/10.1038/nrendo.2013.57>.
126. Shashi V, McConkie-Rosell A, Rosell B, Schoch K, Vellore K, McDonald M, et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. *Genet Med*. 2014;16:176–82. <http://dx.doi.org/10.1038/gim.2013.99>.
127. Wheeler E, Huang N, Bochukova E, Keogh JM, Lindsay S, Garg S, et al. Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity. *Nat Genet*. 2012;100:130–4. <http://dx.doi.org/10.1016/j.pestbp.2011.02.012>.
128. Hasstedt SJ, Xin Y, Mao R, Lewis T, Adams TD, Hunt SC. A copy number variant on chromosome 20q13.3 implicated in thinness and severe obesity. *J Obes*. 2015;2015:1–7. <http://dx.doi.org/10.1155/2015/623431>.
129. Dina C, Meyre D, Gallina S, Durand E, Körner A, Jacobson P, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. *Nat Genet*. 2007;39:724–6. <http://dx.doi.org/10.1038/ng2048>.
130. Grant SF, Li M, Bradfield JP, Kim CE, Annaiah K, Santa E, et al. Association analysis of the FTO gene with obesity in children of Caucasian and African ancestry reveals a common tagging SNP. *PLoS One*. 2008;3:e1746. <http://dx.doi.org/10.1371/journal.pone.0001746>.
131. Scuteri A, Sanna S, Chen W-M, Uda M, Albai G, Strait J, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. *PLoS Genet*. 2007;3:e115. <http://dx.doi.org/10.1371/journal.pgen.0030115>.
132. Need AC, Shashi V, Hitomi Y, Schoch K, Shianna KV, McDonald MT, et al. Clinical application of exome sequencing in undiagnosed genetic conditions. *J Med Genet*. 2012;49:353–61. <http://dx.doi.org/10.1136/jmedgenet-2012-100819>.
133. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. *N Engl J Med*. 1999;341:879–84. <http://dx.doi.org/10.1056/NEJM199909163411204>.
134. Johar AS, Mastronardi C, Rojas-Villarraga A, Patel HR, Chuah A, Peng K, et al. Novel and rare functional genomic variants in multiple autoimmune syndrome and Sjögren's syndrome. *J Transl Med*. 2015;13:173. <http://dx.doi.org/10.1186/s12967-015-0525-x>.
135. Vélez JI, Lopera F, Patel HR, Johar AS, Cai Y, Rivera D, et al. Mutations modifying sporadic Alzheimer's disease age of onset. *Am J Med Genet B Neuropsychiatr*. 2016;171:1116–30. <http://dx.doi.org/10.1002/ajmg.b.32493>.
136. Ott J, Wang J, Leal SM. Genetic linkage analysis in the age of whole-genome sequencing. *Nat Rev Genet*. 2015;16:275–84. <http://dx.doi.org/10.1038/nrg3908>.
137. Wright CF, Fitzgerald TW, Jones WD, Clayton S, McRae JF, Van Kogelenberg M, et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. *Lancet*. 2015;385:1305–14. [http://dx.doi.org/10.1016/S0140-6736\(14\)61705-0](http://dx.doi.org/10.1016/S0140-6736(14)61705-0).
138. Posey JE, Rosenfeld JA, James RA, Bainbridge M, Niu Z, Wang X, et al. Molecular diagnostic experience of whole-exome sequencing in adult patients. *Genet Med*.

2016. [American College of Medical Genetics and Genomics. Retrieved from <http://dx.doi.org/10.1038/gim.2015.142>].
139. Gilissen C, Hehir-Kwa JY, Thung DT, van de Vorst M, van Bon BWM, Willemsen MH, et al. Genome sequencing identifies major causes of severe intellectual disability. *Nature*. 2014;511:344–7. [Retrieved from <http://dx.doi.org/10.1038/nature13394>].
140. Liu DJ, Leal SM. A novel adaptive method for the analysis of next-generation sequencing data to detect complex trait associations with rare variants due to gene main effects and interactions. *PLoS Genet*. 2010;6:e1001156. [Retrieved from <http://dx.doi.org/10.1371/journal.pgen.1001156>].
141. Farooqi IS, O'Rahilly S. Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity. *Nat Clin Pract Endocrinol Metab*. 2008;4:569–77. [Retrieved from <http://dx.doi.org/10.1038/ncpendmet0966>].
142. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric obesity—assessment, treatment, and prevention: an endocrine society clinical practice guideline. *J Clin Endocrinol Metabol*. 2017;102:709–57.
143. Farooqi IS, O'Rahilly S. Genetic obesity syndromes. In: Grant SFA, ed. The genetics of obesity. New York, NY: Springer New York; 2014. p. 23–32, http://dx.doi.org/10.1007/978-1-4614-8642-8_2.
144. Philippe J, Derhourhi M, Durand E, Vaillant E, Dechaume A, Rabearivelo I, et al. What is the best NGS enrichment method for the molecular diagnosis of monogenic diabetes and obesity? *PLoS One*. 2015;10:e0143373, <http://dx.doi.org/10.1371/journal.pone.0143373>.
145. Reinehr T, Hebebrand J, Friedel S, Toschke AM, Brumm H, Biebermann H, et al. Lifestyle intervention in obese children with variations in the melanocortin 4 receptor gene. *Obesity*. 2009;17:382–9, <http://dx.doi.org/10.1038/oby.2008.422>.
146. Steffen R, Potoczna N, Bieri N, Horber FF. Successful multi-intervention treatment of severe obesity: a 7-year prospective study with 96% follow-up. *Obes Surg*. 2009;19:3–12, <http://dx.doi.org/10.1007/s11695-008-9675-8>.
147. Aslan IR, Campos GM, Calton MA, Evans DS, Merriman RB, Vaisse C. Weight loss after Roux-en-Y gastric bypass in obese patients heterozygous for MC4R mutations. *Obes Surg*. 2011;21:930–4, <http://dx.doi.org/10.1007/s11695-010-0295-8>.
148. Censani M, Conroy R, Deng L, Oberfield SE, McMahon DJ, Zitsman JL, et al. Weight loss after bariatric surgery in morbidly obese adolescents with MC4R mutations. *Obesity*. 2014;22:225–31, <http://dx.doi.org/10.1002/oby.20511>.
149. Bonnefond A, Keller R, Meyre D, Stutzmann F, Thuillier D, Stefanov DG, et al. Eating behavior, low-frequency functional mutations in the melanocortin-4 receptor (MC4R) gene, and outcomes of bariatric operations: a 6-year prospective study. *Diabetes Care*. 2016;39:1384–92, <http://dx.doi.org/10.2337/dc16-0115>.
150. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. *J Clin Invest*. 2002;110:1093–103, <http://dx.doi.org/10.1172/JCI15693>.
151. Boughton CK, Murphy KG. Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity. *Br J Pharmacol*. 2013;170:1333–48, <http://dx.doi.org/10.1111/bph.12037>.